@RyanRynoT Thanks for that correction. Tuesday.
And I'm fine with the lower price from a shakeout. My plan was to always hold in anticipation for Q3 anyways. I get to average down now
$SLN The "digital smoke" is getting thick. π΅οΈββοΈ Just audited the IR server (q4cdn) and weβve got a massive technical shift. The /2026/ directory just flipped from a 403 Forbidden to a 302 Redirect. 1/x
@RyanRynoT No clue. Price today's terrible. The only day that makes sense is Monday. If nothing happens then, I think we'll be forced to wait until Q3.
@RyanRynoT For sure. Tomorrow's the last day so I'm hoping we get the news then but things could still be getting negotiated and if so, we'll have to be patient but I'm really hoping what we're seeing means we won't wait long for it.
@RyanRynoT Under the UK Takeover Code, if a company is in an "offer period," they are legally required to have a dedicated section on their website for all documents related to the offer. The sudden appearance (and then "hiding") of this path is a strong indicator of tactical preparation.
@RyanRynoT The sitemap instructions were tightened on January 7, 2026. This move effectively "hid" the newly created /investors/offer/ and /transaction-details/ folders from public search engines just 48 hours before the JPM conference.
@type You don't "embargo" a routine presentation. You embargo a Merger Announcement. Don't forget the Jan 6th Form 4sβthe entire board (Ross, Hellums, etc.) converted their options to common shares 8 days ago. They cleaned the cap table for a reason. 3/x
A 302 redirect means the content is STAGED and LIVE on the backend, but they are temporarily routing traffic away until the exact "Go-Live" timestamp. Combine that with the new https://t.co/qGXXQOZRGr "@type: Event" tags that just hit the header code for Jan 14th. 2/x
$SLN The administrative trail for Silence Therapeutics has shifted from routine partnership to a definitive buyout signature. It started on December 1 when AstraZeneca management met with Rothschild in London to lock the valuation models. 1/x
@RyanRynoT It's undervalued. Great platform pumping out two basically best in class products with potential for more. Plus ironclad patents since they went up against alnylam and won. Only shares on my end. When do your options expire?
$SLN The Stereogenic Moat: Better than Arrowhead. Silenceβs mRNAi GOLD platform focuses on reducing undefined stereogenic centers in the siRNA molecule. Most siRNA is a messy mixture of slightly different molecules. Silence has figured out how to make their drug structurally pure